Perspective Therapeutics
CATX
43 hedge funds and large institutions have $5.19M invested in Perspective Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
10% more funds holding
Funds holding: 39 → 43 (+4)
0.06% more ownership
Funds ownership: 1.12% → 1.18% (+0.06%)
10% less capital invested
Capital invested by funds: $5.79M → $5.19M (-$597K)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
+$168K |
| 2 |
TMWM
Taylor & Morgan Wealth Management
Flint,
Michigan
|
+$68.8K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$35.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$9.69K |
| 5 |
VF
Virtu Financial
New York
|
+$7.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$26.2K |
| 2 |
Renaissance Technologies
New York
|
-$12.3K |
| 3 |
BIM
Bullseye Investment Management
Cincinnati,
Ohio
|
-$9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$5.25K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
CATX Hedge Fund Activity: Q2 2022 in Review
43 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2022, worth a combined $5.19M — down 10% from $5.79M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CATX positions and 4 closed out — a net gain of 4 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Venator Capital Management, opening a new position worth an estimated $168K. The largest seller was Citadel Advisors, cutting an estimated $26.2K.
- 43 institutional investors held Perspective Therapeutics (CATX) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $5.19M of Perspective Therapeutics stock for Q2 2022, down 10% quarter-over-quarter.
- 8 funds opened new Perspective Therapeutics positions in Q2 2022 and 4 closed out, a net change of +4 holders.
- The largest Perspective Therapeutics buyer in Q2 2022 was Venator Capital Management, an estimated $168K added.
- The largest Perspective Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $26.2K sold.
Based on aggregated 13F filings for Q2 2022.